| Diabetes Mellitus
Fiasp vs Levemir
Side-by-side clinical, coverage, and cost comparison for diabetes mellitus.Deep comparison between: Fiasp vs Levemir with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsLevemir has a higher rate of injection site reactions vs Fiasp based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Levemir but not Fiasp, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Fiasp
Levemir
At A Glance
SC injection
With meals
Rapid-acting insulin analog
SC injection
Once or twice daily
Long-acting basal insulin analog
Indications
- Diabetes Mellitus
- Diabetes Mellitus
Dosing
Diabetes Mellitus - SC injection Inject at start of meal or within 20 minutes after starting a meal into abdomen, upper arm, or thigh; generally use with intermediate- or long-acting insulin; individualize dose based on metabolic needs and blood glucose monitoring.
Diabetes Mellitus - Insulin pump (CSII) Administer by continuous SC infusion using an insulin pump; change FIASP reservoir at least every 6 days or PumpCart at least every 4 days; do not mix with other insulins in the pump.
Diabetes Mellitus - IV infusion Administer only under medical supervision; dilute to 0.5-1 unit/mL in polypropylene infusion bags with 0.9% sodium chloride or 5% dextrose; stable at room temperature for 24 hours.
Diabetes Mellitus (Type 1) Approximately one-third to one-half of the total daily insulin dose SC once or twice daily in combination with rapid-acting or short-acting insulin; initial total daily dose 0.2-0.4 units/kg in insulin-naive patients.
Diabetes Mellitus (Type 2) 10 units (or 0.1-0.2 units/kg) SC once daily in the evening or divided into a twice-daily regimen in patients inadequately controlled on oral antidiabetic medications or a GLP-1 receptor agonist.
Contraindications
- Episodes of hypoglycemia
- Known hypersensitivity to insulin aspart or any excipient in FIASP
- Episodes of hypoglycemia
- Hypersensitivity to insulin detemir or any excipient in LEVEMIR, including reactions such as anaphylaxis
Adverse Reactions
Most common (>=5%) Nasopharyngitis, upper respiratory tract infection, nausea, diarrhea, back pain (adults with T1D); urinary tract infection (adults with T2D); viral upper respiratory tract infection, upper respiratory tract infection, influenza, headache, pyrexia, vomiting (pediatric T1D)
Serious Hypoglycemia, hypokalemia, severe hypersensitivity reactions including anaphylaxis, angioedema, bronchospasm, hypotension, and shock; lipodystrophy; injection or infusion site reactions; peripheral edema; weight gain
Postmarketing Localized cutaneous amyloidosis at injection site; hyperglycemia with repeated injections into amyloidosis areas; hypoglycemia with sudden change to unaffected injection site
Most common (>=5%) Upper respiratory tract infection, headache, pharyngitis, influenza-like illness, abdominal pain, hypoglycemia
Serious Severe hypoglycemia, anaphylaxis, generalized skin reactions, angioedema, bronchospasm, hypotension, shock, lipodystrophy, peripheral edema, hypokalemia
Postmarketing Medication errors with accidental administration of other insulins instead of LEVEMIR, localized cutaneous amyloidosis, hyperglycemia or hypoglycemia associated with injection into amyloidosis sites
Pharmacology
Rapid-acting insulin analog; binds to insulin receptors to lower blood glucose by facilitating cellular uptake of glucose into skeletal muscle and adipose tissue and inhibiting hepatic glucose output, while also inhibiting lipolysis and proteolysis and enhancing protein synthesis.
Long-acting basal human insulin analog that regulates glucose metabolism by stimulating peripheral glucose uptake in skeletal muscle and fat and inhibiting hepatic glucose production; prolonged duration of action is mediated by self-association of drug molecules at the injection site and albumin binding in the bloodstream.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Fiasp
- Covered on 5 commercial plans
- PA (8/12) · Step Therapy (9/12) · Qty limit (8/12)
Levemir
- Covered on 5 commercial plans
- PA (7/12) · Step Therapy (1/12) · Qty limit (0/12)
UnitedHealthcare
Fiasp
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Levemir
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Fiasp
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (0/3)
Levemir
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (1/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Fiasp.
No savings programs available for Levemir.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
LevemirView full Levemir profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.